Last reviewed 2026-04-19 · How we verify

DOMITROBAN

Phase 2 active Small molecule

DOMITROBAN is a domitroban drug. It is currently in Phase 2 development.

DOMITROBAN blocks the action of thromboxane A2, a substance that promotes blood clotting.

DOMITROBAN is a small molecule drug that targets the thromboxane A2 receptor. It is classified as a domitroban, but its commercial status and approved indications are unknown. DOMITROBAN works by inhibiting the action of thromboxane A2, a substance that promotes blood clotting. As a result, it may be used to treat conditions related to excessive blood clotting, although its specific indications are not specified. Further information on its development, approval, and safety profile is needed.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DOMITROBAN
Drug class	domitroban
Target	Thromboxane A2 receptor, Thromboxane A2 receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Think of thromboxane A2 like a messenger that tells blood cells to stick together and form clots. DOMITROBAN acts like a 'blocker' that prevents this messenger from doing its job, which can help prevent unwanted blood clots from forming.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DOMITROBAN CI brief — competitive landscape report
DOMITROBAN updates RSS · CI watch RSS

Frequently asked questions about DOMITROBAN

What is DOMITROBAN?

DOMITROBAN is a domitroban drug.

How does DOMITROBAN work?

DOMITROBAN blocks the action of thromboxane A2, a substance that promotes blood clotting.

What drug class is DOMITROBAN in?

DOMITROBAN belongs to the domitroban class. See all domitroban drugs at /class/domitroban.

What development phase is DOMITROBAN in?

DOMITROBAN is in Phase 2.

What does DOMITROBAN target?

DOMITROBAN targets Thromboxane A2 receptor, Thromboxane A2 receptor and is a domitroban.

Drug class: All domitroban drugs
Target: All drugs targeting Thromboxane A2 receptor, Thromboxane A2 receptor
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing